Doublet Therapy Ups Survival in Metastatic Prostate Cancer
The use of doublet therapy has increased survival by 6 months, on average, in men with de novo metastatic castration-sensitive prostate cancer, according to Swedish registry data.
Medscape Medical News
source https://www.medscape.com/viewarticle/997343?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/997343?src=rss
Comments
Post a Comment